Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Pain, Intractable 1Cancer Pain 1

Interventions

Specimen Handling 288Magnetic Resonance Spectroscopy 238pembrolizumab 228Carboplatin 187Cisplatin 153Biopsy 151Cyclophosphamide 144Paclitaxel 133Nivolumab 123Gemcitabine 113Bevacizumab 106Radiotherapy 96Dexamethasone 86Pemetrexed 83fludarabine 78Fluorouracil 76Doxorubicin 76Docetaxel 76atezolizumab 73Radiation 72Leucovorin 70Rituximab 68Oxaliplatin 66venetoclax 61durvalumab 61Prednisone 61Vincristine 56Cetuximab 56Lenalidomide 55Etoposide 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
resiniferatoxin × 30 days × Clear all
NCT02522611 2026-06-01

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

National Institutes of Health Clinical Center (CC)

Phase 1/2 Not yet recruiting
30 enrolled

Cancer Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡